BIOATLA INC. - COMMON

1,6400

27-ноября-24 15:45:00

15 мин. задержка

Акции

+0,0700

+4,46%

Сегодняшний диапазон

1,5700 - 1,6700

ISIN

N/A

Источник

NASDAQ

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

07 ноя 2024 15:01:00 Источник Nasdaq GlobeNewswire
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

31 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

04 окт 2024 08:05:00 Источник Nasdaq GlobeNewswire
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

01 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

23 сен 2024 06:30:00 Источник Nasdaq GlobeNewswire
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

16 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

09 сен 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

28 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

08 авг 2024 15:05:00 Источник Nasdaq GlobeNewswire
BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024

01 авг 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioAtla Highlighted Clinical Program and Pipeline Updates at Virtual R&D Day

25 июл 2024 16:39:55 Источник Nasdaq GlobeNewswire
BioAtla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (CAB-ROR2-ADC) for Treatment of Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

23 июл 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024

27 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioAtla to Participate in the Jefferies Global Healthcare Conference

29 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 май 2024 16:05:00 Источник Nasdaq GlobeNewswire
BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress

14 май 2024 15:05:00 Источник Nasdaq GlobeNewswire
BioAtla to Participate in the Citizens JMP Life Sciences Conference

08 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024

07 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3361, a CAB-Nectin-4 Antibody Drug Conjugate for the Treatment of Multiple Tumors

06 май 2024 07:00:00 Источник Nasdaq GlobeNewswire
BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 апр 2024 15:35:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.